MacroGenics (MGNX) investor relations material

Strategic and financial updates

• Announced two major transactions: a ZYNYZ royalty monetization with Sagard Health ($60M received, up to $80M total) and a $122.5M manufacturing sale to Bora Pharmaceuticals, potentially bringing in over $200M in near-term cash.

• Pro forma cash balance projected at over $330M, extending financial runway through 2028.

• ZYNYZ royalty deal terms improved, lowering Sagard's return multiple from 2.0x to 1.7x due to strong product performance and new approvals.

• Retains rights to develop ZYNYZ in combination with internal pipeline assets; manufacturing obligations to transfer to Bora upon deal closure by Q3 2024.

• Aggregate value of remaining royalty milestones is approximately $540M, with royalties ranging from 15%-24%.

Pipeline and clinical development

• Lorigerlimab phase II LYNET trial in clear cell gynecological cancers showed encouraging response rates but notable hematological toxicities; dose reduction to 3mg planned to improve safety.

• Platinum-resistant ovarian cancer cohort discontinued due to insufficient efficacy; clear cell data update expected in H1 2025.

• Focus on identifying responsive subgroups through translational research and considering expansion into other tumor types if data supports.

• Resource allocation for lorigerlimab remains modest, with further clarity expected after dosing 20 additional patients at 3mg.

ADC and early-stage pipeline progress

• MGC026 (B7-H3 ADC) leverages site-specific GlycoConnect linker and potent exatecan payload, aiming for improved therapeutic index and safety; mid-2024 data update planned.

• B7-H3 ADC program positioned for differentiation based on construct design and development strategy, with lead indications to be announced.

• MGC028 (ADAM9 ADC) is first-in-class, with dose escalation ongoing and a broad range of GI and lung cancer indications under evaluation; clinical update expected in H2 2024.

• Competitive landscape for ADCs is intensifying, especially from China-based entrants.